company background image
FRE

Firebrick Pharma ASX:FRE Stock Report

Last Price

AU$0.24

Market Cap

AU$39.8m

7D

-3.9%

1Y

n/a

Updated

06 Dec, 2022

Data

Company Financials
FRE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

FRE Stock Overview

Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia.

Firebrick Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Firebrick Pharma
Historical stock prices
Current Share PriceAU$0.24
52 Week HighAU$0.75
52 Week LowAU$0.23
Beta0
1 Month Change2.08%
3 Month Change-25.76%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-53.77%

Recent News & Updates

Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Aug 30
Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Recent updates

Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Aug 30
Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Shareholder Returns

FREAU PharmaceuticalsAU Market
7D-3.9%-6.1%1.0%
1Yn/a-26.2%-2.2%

Return vs Industry: Insufficient data to determine how FRE performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how FRE performed against the Australian Market.

Price Volatility

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement10.2%
Market Average Movement8.9%
10% most volatile stocks in AU Market15.9%
10% least volatile stocks in AU Market4.1%

Stable Share Price: FRE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: FRE's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aPeter Molloyhttps://www.firebrickpharma.com

Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Firebrick Pharma Limited Fundamentals Summary

How do Firebrick Pharma's earnings and revenue compare to its market cap?
FRE fundamental statistics
Market CapAU$39.76m
Earnings (TTM)-AU$3.80m
Revenue (TTM)AU$1.08m

38.3x

P/S Ratio

-10.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FRE income statement (TTM)
RevenueAU$1.08m
Cost of RevenueAU$0
Gross ProfitAU$1.08m
Other ExpensesAU$4.88m
Earnings-AU$3.80m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.022
Gross Margin100.00%
Net Profit Margin-350.42%
Debt/Equity Ratio0.0%

How did FRE perform over the long term?

See historical performance and comparison